Receptor-Interacting Protein Kinase 2 (RIPK2) Stabilizes C-myc and Is a Therapeutic Target in Prostate Cancer Metastasis

Scientists showed RIPK2 was a clinically actionable target for inhibiting prostate cancer (PC) metastasis. RIPK2 was amplified/gained in ~65% of lethal metastatic castration-resistant PC.